| This week's sponsor is TD2. | |  | |
Today's Rundown Featured Story | | | Wednesday, January 10, 2018 SAN FRANCISCO—Six panelists representing biotech, pharma and VC discussed the meaning of good science, how money affects a company's behavior and how different players can work together to leverage their respective strengths and deliver therapies to patients. |
|
|
| This week's sponsor is Veeva. | |  | [Webinar] Tufts eClinical Landscape Study: Q&A with Industry Experts
January 16, 2018 | 2pm ET / 11am PT
Hear expert analysis of the 2017 eClinical Landscape Survey, one of the largest, most in-depth surveys of clinical data management professionals that shows the impact of database build delays on trial timelines, as well as the projected increase of data source usage. Register Now |
Top Stories Wednesday, January 10, 2018 David Hung is the CEO who sold his company, Medivation, to Pfizer for $14 billion. He got the plaudits, a big payday and seemingly a free pass to almost any biopharma job he wanted. Now his decision to join Axovant looks more like a gamble that isn't paying off. Wednesday, January 10, 2018 Evolus has filed for a $75 million IPO. The financing will position Evolus to challenge Allergan’s grip on the wrinkle-busting sector by bringing a biosimilar copy of Botox to market in the U.S. and elsewhere. Monday, January 8, 2018 Astellas, like many of our industry peers, prioritizes innovation. What sets Astellas apart, however, is how we function at the intersection where our “Science First” approach meets the flexibility we’ve built into our innovation infrastructure. Wednesday, January 10, 2018 Canadian biotech Adapsyn Bioscience has developed a system that could sift out promising drug candidates from microbes more quickly—catching the eye of a big pharma partner. Wednesday, January 10, 2018 Genentech and Syndax have expanded their exploration of the effects of combining HDAC and PD-L1 inhibitors. The new agreement clears the Roche subsidiary to test its Tecentriq in combination with Syndax’s entinostat in a subset of breast cancer patients. Wednesday, January 10, 2018 Our rolling live blog for all the biotech news that's fit to print from J.P. Morgan. Check here frequently for ongoing updates. Wednesday, January 10, 2018 Truffle Capital has held the first close of its BioMedTech venture fund. The French VC shop moved quickly to put the initial $102 million to use by setting up and financing three startups in its home country. | This week's sponsor is Protea Biosciences. | | Protea's “BIOPHARMA” Assets Available For Sale in Morgantown, WV (Ch. 11 Debtor) - Cancer-Diagnostic Protocols, Lab EQ, & Licenses ($1.15MM Min)
- Stalking Horse Bid at $1.0MM Already Filed; Sale Hearing Date 01/24/18
- Small Molecule Analytics Business, EQ, & Cust. AR + $75.0MM NOLs ($1.0MM Min)
All assets to be sold via 363-Sale Auctions (No. Distr. of WV BK Court - Case: 17-1200) Bids are due by January 18, 2018 (Unless Extended) Contact: Jack Teitz, CRO for Additional Information: 412-855-7625 |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: SDC Clinical : What do you do when timelines are missed, data is dirty, and everyone is pointing fingers? From study delays to quality issues, sponsors can find their studies at risk with no clear solution. Sponsored by: Veeva Systems Expanding into new markets places a spotlight on inefficient processes. Sponsored by: Seton Hall Don’t miss this educational program trusted by multi-national companies as part of their employee’s compliance training. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating in the Asia-Pacific region. Visit event page for session topics. Sponsored by: Agilent This Agilent intact protein analysis includes: Sponsored by: Veeva Systems Regulatory leaders share challenges and best practices from a lack of standardization, manual processes, and fragmented systems. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Presented By: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. | 
